Ofatumumab
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Leukaemia, Lymphocytic, Chronic
Conditions
Leukaemia, Lymphocytic, Chronic
Trial Timeline
Jan 1, 2009 → May 1, 2013
NCT ID
NCT00802737About Ofatumumab
Ofatumumab is a approved stage product being developed by Genmab for Leukaemia, Lymphocytic, Chronic. The current trial status is completed. This product is registered under clinical trial identifier NCT00802737. Target conditions include Leukaemia, Lymphocytic, Chronic.
What happened to similar drugs?
1 of 7 similar drugs in Leukaemia, Lymphocytic, Chronic were approved
Approved (1) Terminated (3) Active (3)
Hype Score Breakdown
Clinical
20
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00802737 | Approved | Completed |
Competing Products
20 competing products in Leukaemia, Lymphocytic, Chronic